DSPE Regulatory Update: Acceptance Of The European Medicines Agency Submission For An Atypical Antipsychotic Agent Lurasidone

Dainippon Sumitomo Pharma Europe Ltd ("DSPE") (Headquarters: London, UK) today announced that the European Medicines Agency (EMA) has confirmed that the Marketing Authorisation Application (MAA) for lurasidone hydrochloride, an atypical antipsychotic investigational medicine for the treatment of schizophrenia, is valid. The MAA was filed by Takeda Global Research & Development Centre (Europe). Dainippon Sumitomo Pharma Co., Ltd ("DSP") discovered and developed lurasidone... via Health News from Medical News Today Read More Here..